Leukemia & Lymphoma最新文献_第8页

Donor IL-10 and FOXP3 single-nucleotide polymorphisms associated with post-transplantation outcomes. 供体IL-10和FOXP3单核苷酸多态性与移植后预后相关。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-25 DOI: 10.1080/10428194.2025.2550576

Hirotaro Sakaki, Misuzu Sato, Mami Umemoto, Ayano Shirai, Kazuki Nagao, Hidenori Hayashi, Natsuki Kawamata, Kai Kuroiwa, Hinako Narita, Reiko Okamura, Shotaro Shimada, Megumi Watanuki, Nana Arai, Kouji Yanagisawa, Keiichi Iezumi, Norimichi Hattori

{"title":"Donor IL-10 and FOXP3 single-nucleotide polymorphisms associated with post-transplantation outcomes.","authors":"Hirotaro Sakaki, Misuzu Sato, Mami Umemoto, Ayano Shirai, Kazuki Nagao, Hidenori Hayashi, Natsuki Kawamata, Kai Kuroiwa, Hinako Narita, Reiko Okamura, Shotaro Shimada, Megumi Watanuki, Nana Arai, Kouji Yanagisawa, Keiichi Iezumi, Norimichi Hattori","doi":"10.1080/10428194.2025.2550576","DOIUrl":"https://doi.org/10.1080/10428194.2025.2550576","url":null,"abstract":"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potential cure for hematologic malignancies, but post-transplant complications, particularly graft-versus-host disease (GVHD), remain major challenges. Regulatory T cells and interleukin-10 (IL-10) play key roles in immune regulation. This retrospective study investigated the impact of donor FOXP3-3279 (rs3761548) and IL-10-819 (rs1800871) single-nucleotide polymorphisms (SNPs) on clinical outcomes in 92 allo-HSCT recipients, with emphasis on umbilical cord blood transplantation (UCBT). Among UCBT recipients, non-C/C FOXP3 and non-T/T IL-10 donor genotypes were associated with significantly worse progression-free and overall survival, as well as a higher incidence of chronic GVHD. Multivariable analyses confirmed the prognostic impact of these SNPs. These findings suggest that donor-derived SNPs in key immune regulatory genes may influence post-transplant immune reconstitution. FOXP3 and IL-10 genotyping could serve as useful biomarkers to guide donor selection and risk stratification in UCBT settings, potentially improving transplantation outcomes.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Indolent chronic myeloid leukemia - a historical dinosaur? 惰性慢性髓性白血病——历史上的恐龙？

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-22 DOI: 10.1080/10428194.2025.2536121

Jeffrey H Lipton

引用次数: 0

Graft-versus-tumor effect in autologous setting: fact or fallacy? 自体移植物抗肿瘤效应：事实还是谬误？

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-21 DOI: 10.1080/10428194.2025.2547986

Anu Partanen, Tuure Kinnunen, Esa Jantunen

引用次数: 0

Lite-BEAM expands autologous stem cell transplantation access for older or unfit patients with lymphoma. Lite-BEAM扩大了老年或不适合淋巴瘤患者的自体干细胞移植途径。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-21 DOI: 10.1080/10428194.2025.2547985

Piyatida Chumnumsiriwath, Pongthep Vittayawacharin, Lauren Pinter-Brown, Elizabeth A Brem, Shawn P Griffin, Piyanuch Kongtim, Stefan O Ciurea

引用次数: 0

Flow cytometric and molecular MRD in AML: current methods, clinical applications and challenges. AML的流式细胞术和分子MRD：目前的方法、临床应用和挑战。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-20 DOI: 10.1080/10428194.2025.2547993

Lukas H Haaksma, Jacqueline Cloos, David C de Leeuw

{"title":"Flow cytometric and molecular MRD in AML: current methods, clinical applications and challenges.","authors":"Lukas H Haaksma, Jacqueline Cloos, David C de Leeuw","doi":"10.1080/10428194.2025.2547993","DOIUrl":"10.1080/10428194.2025.2547993","url":null,"abstract":"Measurable residual disease (MRD) in acute myeloid leukemia (AML) provides prognostic information beyond molecular risk classification at diagnosis, facilitating personalized treatment strategies and improved patient outcomes. This review focuses on the clinical implementation of MRD in patients in remission after induction therapy. We discuss the three primary methods for MRD detection, including multiparameter flow cytometry (MFC), polymerase chain reaction (PCR), and next-generation sequencing (NGS), highlighting their respective prognostic value, strengths, and limitations. We review the clinical application of MRD in guiding consolidation treatment, particularly regarding (de)-intensification of allogeneic stem cell transplantation. Additionally, we address evidence on the utility of MRD in selecting conditioning intensity, stem cell source, and additional pre-consolidation treatment. Currently, the main challenge of MRD is methodological standardization and harmonization across laboratories, which is being addressed by several international working parties. In this context, the value of combining MRD methods and leveraging their respective strengths should be further evaluated.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy. 奥曲塞单抗单药治疗复发/难治性弥漫性大b细胞淋巴瘤患者报告的结果

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-20 DOI: 10.1080/10428194.2025.2535694

Elżbieta Iskierka-Jażdżewska, Won Seog Kim, Seok-Goo Cho, Tae Min Kim, Isidro Jarque, Tadeusz Robak, Michelle Poon, H Miles Prince, Sung Yong Oh, Francesca Lim, Cecilia Carpio, Tran-Der Tan, Sabarish Ayyappan, Antonio Gutierrez, Huilai Zhang, Junning Cao, Benoit Tessoulin, Jingjin Li, Cristina Ivanescu, Matthew Reaney, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, James Harnett, Lei Chi, Siddhesh Kamat, Jan Walewski

{"title":"Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.","authors":"Elżbieta Iskierka-Jażdżewska, Won Seog Kim, Seok-Goo Cho, Tae Min Kim, Isidro Jarque, Tadeusz Robak, Michelle Poon, H Miles Prince, Sung Yong Oh, Francesca Lim, Cecilia Carpio, Tran-Der Tan, Sabarish Ayyappan, Antonio Gutierrez, Huilai Zhang, Junning Cao, Benoit Tessoulin, Jingjin Li, Cristina Ivanescu, Matthew Reaney, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, James Harnett, Lei Chi, Siddhesh Kamat, Jan Walewski","doi":"10.1080/10428194.2025.2535694","DOIUrl":"10.1080/10428194.2025.2535694","url":null,"abstract":"In the ELM-2 study (NCT03888105) of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (n = 141), odronextamab 160 mg weekly (after step-up dosing) significantly improved Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Lymphoma Subscale (LymS, least squares mean [95% confidence interval], 3.02 [1.76, 4.27]), FACT-General (FACT-G, 2.85 [0.81, 4.90]), Trial Outcome Index (TOI, 4.56 [2.18, 6.94]), and Total Score (5.64 [2.64, 8.64]); as well as European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) global health status/quality of life scale (GHS/QoL, 4.04 [1.23, 6.84]) and EQ-5D-3L visual analog scale (VAS, 3.59 [0.79, 6.39]) for overall health status. The least squares mean improvement in FACT LymS was clinically meaningful and patients were more likely to report clinically meaningful improvement or maintenance than clinically meaningful worsening overall for every scale. These improvements in patient-reported outcomes support the feasibility of odronextamab monotherapy regimen as a potential treatment option in r/r DLBCL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcome of allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia patients who underwent myeloablative TBI-free conditioning regimen. 同种异体造血细胞移植治疗成人急性淋巴细胞白血病的疗效。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-20 DOI: 10.1080/10428194.2025.2548968

Delaram Amiri, Mandana Mirzaei, Tanaz Bahri, Maryam Barkhordar, Negar Nejati, Davood Babakhani, Mohammad Biglari, Marjan Yaghmaie, Soroush Rad, Mohammad Vaezi, Kamran Alimoghadam, Ghasem Janbabai, Seied Asadollah Mousavi, Hossein Kamranzadeh Fumani, Sahar Tavakoli Shirjani, Ardeshir Ghavamzadeh

{"title":"Outcome of allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia patients who underwent myeloablative TBI-free conditioning regimen.","authors":"Delaram Amiri, Mandana Mirzaei, Tanaz Bahri, Maryam Barkhordar, Negar Nejati, Davood Babakhani, Mohammad Biglari, Marjan Yaghmaie, Soroush Rad, Mohammad Vaezi, Kamran Alimoghadam, Ghasem Janbabai, Seied Asadollah Mousavi, Hossein Kamranzadeh Fumani, Sahar Tavakoli Shirjani, Ardeshir Ghavamzadeh","doi":"10.1080/10428194.2025.2548968","DOIUrl":"https://doi.org/10.1080/10428194.2025.2548968","url":null,"abstract":"Acute lymphoblastic leukemia (ALL) predominantly affects children but has poorer outcomes in adults. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a key consolidation therapy for high-risk patients, but the more commonly employed total body irradiation (TBI) regimen may be inaccessible in resource-limited settings, requiring alternative regimens. This retrospective study evaluated outcomes of 829 adult ALL patients who underwent HLA-matched allo-HSCT with a myeloablative, TBI-free regimen over two decades. The study compared overall survival (OS), disease-free survival (DFS), relapse incidence (RI), and non-relapse mortality (NRM) between pre- and post-2010 periods. Post-2010, 5-year OS improved from 38.3% to 48.1% (p = 0.0037), DFS from 36.6% to 42.0% (p = 0.027), and RI decreased from 47.5% to 40.8% (p = 0.012), with more notable improvements in patients ≥25 years. NRM remained stable (28.5% vs. 24.9%, p = 0.599). These findings suggest that a Busulfan-based, TBI-free regimen is a viable alternative, but further efforts are needed to reduce NRM and improve survival.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mortality and relapse dynamics in AML after three years of complete remission. 完全缓解三年后AML的死亡率和复发动态。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-19 DOI: 10.1080/10428194.2025.2547984

Samuel Urrutia, Wei-Ying Jen, Koji Sasaki, Peter H Wiernik, Tapan Kadia, Naval Daver, Courtney D DiNardo, Guillermo Garcia-Manero, Elias Jabbour, Nicholas J Short, Ghayas Issa, Farhad Ravandi, Musa Yilmaz

引用次数: 0

Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1-positive AML: results from AML-CAMS serial trials. 可测量的残留疾病动力学在RUNX1:: runx1t1阳性AML患儿中具有预后意义：来自AML- cams系列试验的结果

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-19 DOI: 10.1080/10428194.2025.2548966

Luyang Zhang, Meihui Yi, Xiaoli Chen, Ye Guo, Xiaojuan Chen, Yumei Chen, Yao Zou, Li Zhang, Xiaofan Zhu, Wenyu Yang, Min Ruan

{"title":"Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1-positive AML: results from AML-CAMS serial trials.","authors":"Luyang Zhang, Meihui Yi, Xiaoli Chen, Ye Guo, Xiaojuan Chen, Yumei Chen, Yao Zou, Li Zhang, Xiaofan Zhu, Wenyu Yang, Min Ruan","doi":"10.1080/10428194.2025.2548966","DOIUrl":"10.1080/10428194.2025.2548966","url":null,"abstract":"Quantitative real-time PCR (qRT-PCR) enables measurable residual disease (MRD) monitoring in RUNX1::RUNX1T1-positive acute myeloid leukemia (AML), guiding treatment in patients with morphological remission. However, the optimal thresholds and timing for MRD assessment remain undefined, particularly in pediatric cases due to the rarity. Our analysis of 136 pediatric patients with RUNX1::RUNX1T1-positive AML revealed that less than a 3-log reduction after induction chemotherapy predicted an inferior prognosis (p < 0.05). However, patients with < 3-log reduction but MRD < 0.01% after two consolidations had outcomes comparable to those with ≥ 3-log reduction. Reduction < 3-log after induction chemotherapy plus MRD ≥ 0.01% after two consolidations was an independent adverse factor for both relapse-free (HR = 4.230, p = 0.016) and overall survival (HR = 5.128, p = 0.045). These findings highlight the prognostic value of early MRD dynamics and support MRD-guided risk stratification in pediatric AML.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144883127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the clinical approach to "pathologically ambiguous follicular lymphoma" through a Real-World cohort. 通过真实世界队列了解“病理模糊滤泡性淋巴瘤”的临床方法。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-18 DOI: 10.1080/10428194.2025.2542943

Sarah Matarasso Greenfeld, Svetlana Dmitrienko, Ian Shrier, Jean Luc Deschenes, Sarit Assouline

引用次数: 0